Literature DB >> 9177987

A comparison of intratracheal and intravenous administration of gentamicin during liquid ventilation.

M A Zelinka1, M R Wolfson, I Calligaro, S D Rubenstein, J S Greenspan, T H Shaffer.   

Abstract

UNLABELLED: Pulmonary absorption of aminoglycosides is poor with intravenous administration, but may be enhanced by direct intratracheal administration of these drugs using perfluorochemical liquid ventilation (LV). To test this hypothesis, gentamicin sulfate was administered to two groups of newborn lambs during LV. Serum and lung tissue levels of gentamicin were compared after either pulmonary intratracheal (IT) or intravenous (IV) routes of administration. Serial serum levels of gentamicin were obtained every 15 min for the 1st h, every 30 min for the 2nd h, and then hourly until sacrifice (maximum 6 h). At sacrifice, representative samples of each lung lobe were homogenized and analyzed for tissue gentamicin content. At 1 h, serum gentamicin levels were similar in both groups: IT administration levels were 3.7 +/- 0.55 SE micrograms/ml and IV levels were 3.5 +/- 0.85 SE micrograms/ml. The peak serum gentamicin level of 4.8 +/- 0.8 SE micrograms/ml for the pulmonary administration group occurred 1.5 h after administration. Lung tissue levels of gentamicin for IT administration (4.04 +/- 0.62 SE micrograms/g) were significantly greater than for IV administration (1.75 +/- 0.33 SE micrograms/g; P < 0.05). There were no significant differences in interlobar gentamicin distribution for either mode of administration.
CONCLUSION: Perfluorochemical can be used as a vehicle for intratracheal delivery of antimicrobials. This route provides equivalent serum levels at 1 h, higher lung tissue levels, and uniform interlobar distribution relative to intravenous administration of gentamicin. We speculate that pulmonary administered gentamicin during LV may provide an effective alternative treatment modality in the management of severe neonatal pneumonia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177987     DOI: 10.1007/s004310050625

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

1.  Liquid ventilation.

Authors:  Qutaiba A Tawfic; Rajini Kausalya
Journal:  Oman Med J       Date:  2011-01

Review 2.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 3.  Administration of Drugs/Gene Products to the Respiratory System: A Historical Perspective of the Use of Inert Liquids.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

4.  Synthesis, physicochemical properties and in vitro cytotoxicity of nicotinic acid ester prodrugs intended for pulmonary delivery using perfluorooctyl bromide as vehicle.

Authors:  Hans-Joachim Lehmler; Ling Xu; Sandhya M Vyas; Vivian A Ojogun; Barbara L Knutson; Gabriele Ludewig
Journal:  Int J Pharm       Date:  2007-11-17       Impact factor: 5.875

5.  [Preserved spontaneous breathing during partial liquid ventilation. Results of experimental animal studies and their clinical implications].

Authors:  H D Hummler; F Pohlandt; A Schulze
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 6.  Liquid ventilation.

Authors:  Suman Sarkar; Anil Paswan; S Prakas
Journal:  Anesth Essays Res       Date:  2014 Sep-Dec

7.  Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Authors:  Marla R Wolfson; Perenlei Enkhbaatar; Satoshi Fukuda; Christina L Nelson; Robert O Williams; Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Gennaro Calendo; Andrey A Komissarov; Galina Florova; Krishna Sarva; Steven I Idell; Thomas H Shaffer
Journal:  Clin Transl Med       Date:  2020-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.